Valuation: Mylan N.V.

Market Cap 22.83B 20.47B 18.71B 17.08B 32.18B 2,146B 33.19B 226B 89.93B 1,145B 85.68B 83.84B 3,614B P/E 2026 *
-271x
P/E 2027 * 92.9x
Enterprise Value 34.47B 30.92B 28.26B 25.79B 48.6B 3,240B 50.13B 341B 136B 1,729B 129B 127B 5,458B EV / Sales 2026 *
2.33x
EV / Sales 2027 * 2.2x
Free-Float
90.95%
Yield 2026 *
2.54%
Yield 2027 * 2.62%
Manager TitleAgeSince
Chief Executive Officer 63 2023-03-31
Director of Finance/CFO 59 2026-05-07
Chief Tech/Sci/R&D Officer - 2023-12-14
Director TitleAgeSince
Director/Board Member 78 2020-11-15
Director/Board Member 78 2020-11-15
Director/Board Member 62 2020-11-15
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+1.37% - - 22.83B
-0.79%-4.48%+46.48%+125.69% 1,206B
+1.43%+1.11%+48.05%+83.05% 665B
+1.07%-1.21%+32.92%+104.92% 515B
-0.36%-3.25%+45.42%+65.10% 381B
-0.14%-1.87%+70.06%+41.09% 362B
-0.78%-0.52%+30.47%+58.09% 307B
-0.80%-0.21%+7.98%+36.17% 289B
+0.03%-1.20%+43.79%+69.83% 249B
-0.41%-2.22%+40.43%+107.03% 207B
Average +0.12%-1.54%+40.62%+76.77% 464.42B
Weighted average by Cap. -0.03%-1.96%+42.71%+88.11%

Financials

2026 *2027 *
Net sales 14.8B 13.28B 12.13B 11.08B 20.87B 1,392B 21.53B 146B 58.32B 743B 55.57B 54.38B 2,344B 15.35B 13.77B 12.58B 11.49B 21.64B 1,443B 22.32B 152B 60.48B 770B 57.62B 56.38B 2,431B
Net income -115M -103M -93.93M -85.74M -162M -10.77B -167M -1.13B -451M -5.75B -430M -421M -18.15B 306M 274M 251M 229M 431M 28.75B 445M 3.02B 1.2B 15.34B 1.15B 1.12B 48.42B
Net Debt 11.64B 10.44B 9.55B 8.71B 16.42B 1,095B 16.93B 115B 45.88B 584B 43.71B 42.77B 1,844B 10.96B 9.83B 8.99B 8.2B 15.45B 1,030B 15.94B 108B 43.19B 550B 41.15B 40.26B 1,736B
Logo Mylan N.V.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Mylan N.V.